North America Biosimilars Market Emerging Technologies, Segmentation, Future Plans 2028

The North America Biosimilars Market is expected to grow from US$ 7,115.74 million in 2022 to US$ 47,746.80 million by 2028. It is estimated to grow at a CAGR of 37.3% from 2022 to 2028.

Get Full Report: https://www.businessmarketinsights.com/reports/north-america-biosimilars-market

Growing Prevalence of Chronic Diseases Fuels North America Biosimilars Market

The rising incidence of chronic diseases, key driver of the North America Biosimilars Market. Factors such as an aging population, evolving social behaviors, and the increasing adoption of sedentary lifestyles due to rapid urbanization have contributed to a surge in conditions like obesity and diabetes. Genetic predisposition also plays a significant role in chronic illnesses, including cardiovascular diseases (CVDs), diabetes, Alzheimer's disease (AD), and depression. According to the National Council on Aging, 80% of adults aged 65 and older have at least one chronic condition, with 68% experiencing two or more. Additionally, the Centers for Disease Control and Prevention (CDC) reported in 2020 that nearly six in ten Americans had at least one chronic disease, while four in ten suffered from two or more.

Cardiovascular diseases such as atherosclerosis, angina pectoris, and acute myocardial infarction are leading causes of mortality worldwide, exacerbated by high-stress lifestyles. The World Health Organization (WHO) estimates that CVDs account for 17.9 million deaths annually, making them the top global cause of death. Meanwhile, diabetes remains a major health concern with no functional cure, often leading to severe complications such as heart attacks, strokes, kidney failure, amputations, vision loss, and nerve damage.

According to the International Diabetes Federation (IDF), diabetes cases in North America are projected to rise from 46 million in 2017 to 62 million by 2045. Globally, diabetes cases are expected to grow from 425 million in 2017 to 629 million in 2045, representing a 35% increase in prevalence over the forecast period.

North America Biosimilars Market Segments Covered

North America Biosimilars Market By Disease Indication

Cancer
Diabetes
Autoimmune Diseases
Other Diseases

North America Biosimilars Market By Drug Class

Granulocyte Colony-Stimulating Factors
Human Growth Hormone
Insulin
TNF Blockers & Monoclonal Antibodies
Erythropoietin-Stimulating Agents

North America Biosimilars Market By Route of Administration

Intravenous
Subcutaneous

North America Biosimilars Market By End User

Hospitals
Speciality Clinics
Homecare

North America Biosimilars Market Regions and Countries Covered

North America

US
Canada
Mexico

North America Biosimilars Market leaders and key company profiles

Amgen Inc
Celltrion Inc
Sanofi SA
Biocon Ltd
Coherus BioSciences Inc
Eli Lilly and Co
Sandoz AG
Teva Pharmaceutical Industries Ltd
Pfizer Inc
Dr. Reddy's Laboratories Ltd

North America Biosimilars Market Overview

Autoimmune diseases are also on the rise, further expanding the need for biosimilars. In 2019, the NIH Autoimmune Diseases Coordinating Committee reported that over 24 million Americans were affected by autoimmune diseases, with an additional 8 million showing auto-antibodies-biomarkers that indicate a higher risk of developing such conditions. Research from the National Institute of Environmental Health Sciences (NIEHS) in 2020 highlighted a significant increase in the prevalence of antinuclear antibodies (ANA), the most common biomarker for autoimmunity, across diverse demographics in the U.S.

Biosimilars are increasingly used to treat cancers, kidney diseases, diabetes, and autoimmune conditions such as rheumatoid arthritis and Crohn's disease. According to Cardinal Health, the FDA has approved 33 biosimilars in the U.S., with 21 commercially available. Of these, 17 are used in cancer treatment, three target autoimmune conditions, and one addresses diabetes.

Strategic Insights into the North America Biosimilars Market

Strategic analysis of the North America biosimilars market provides valuable insights into industry trends, key players, and regional dynamics. A data-driven approach enables businesses to identify untapped market segments and craft unique value propositions to gain a competitive edge. By leveraging analytics, stakeholders-including investors, manufacturers, and healthcare providers-can anticipate market shifts and align their strategies for long-term success. A forward-looking perspective is crucial in this evolving landscape, allowing industry players to make informed decisions, maximize profitability, and achieve their business objectives within the growing biosimilars sector.

Other Reports:

North America Small Satellite Market: https://sites.google.com/view/northamericasmallsatellitemark/home

North America Hydrocephalus Shunts Market: https://business-news-insights.blogspot.com/2025/04/north-america-hydrocephalus-shunts.html

North America Airway Management Devices Market: https://postyourarticle.com/north-america-airway-management-devices-market-significant-growth-technological-advancement-2028/

North America Ammunition Market: https://businessnews46.wordpress.com/2025/04/01/north-america-ammunition-market-trends-opportunities-by-2028/

Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Ankit Mathur
Phone: +16467917070
Email: sales@businessmarketinsights.com

About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.

This release was published on openPR.